🇺🇸 FDA
Pipeline program

deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

IM011-1128

Phase 3 small_molecule active

Quick answer

deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use for Moderate to Severe Plaque Psoriasis is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Moderate to Severe Plaque Psoriasis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials